|
| |
| |
|
|
|
2007 News Releases
- Nov 20, 2007 Senior Management Changes
- Nov 15, 2007 WEX Reports Second Quarter Results
- Oct 18, 2007 Appointment of Chief Financial Officer
- Oct 17, 2007 Private Placement Closes
- Oct 16, 2007 Comprehensive Litigation Settlement
- Oct 2, 2007 Results of Post Hoc Analysis of Tectin (TM) Clinical Trial Accepted For Publication
- Sep 20, 2007 Closing of Transaction with CKLS Deferred
- Sep 18, 2007 Two Canadian Patents Issued
- Sep 18, 2007 WEX Announces Results of Shareholder Meeting
- Sep 13, 2007 WEX Reports First Quarter Results
- Sep 12, 2007 Default Status Report
- Sep 5, 2007 A.J. Miller Announces Support of WEX Pharmaceutical Management
- Aug 29, 2007 Default Status Report
- Aug 20, 2007 Management Cease Trade Order Granted
- Aug 16, 2007 New Date Set for AGM - Acting CFO Resigns
- July 30, 2007 Shareholders' Meeting Rescheduled
- July 16, 2007 WEX Announces $20 Million Financing
- June 29, 2007 Year End Financial Results
- June 15, 2007 WEX Receives No Objection Letter from Health Canada for Phase III Clinical Trial in Cancer Pain
- June 8, 2007 Update on Situation in Nanning Maple Leaf Pharmaceutical Co., Ltd
- May 29, 2007 Tianjin's Response to the Legal Proceedings
- May 25, 2007 WEX Reconstitutes Scientific Advisory Board
- May 14, 2007 WEX and Esteve Terminate Collaboration on Tetrodotoxin
- May 9, 2007 WEX Files Clinical Trial Application with Health Canada for Tectin™
- April 13, 2007 WEX Receives Tianjin's Defence and Counterclaim
- Feb 14, 2007 WEX Reports Third Quarter Reports
- Jan 10, 2007 Option Amendments Approved
< 2006 news
|
 |
|
|
|
| Home | News | Corporate | Products | Clinical Trials | Investors | Licensing | Contact | |
|
Copyright WEX Pharmaceuticals Inc. All rights reserved.
Privacy Policy | Disclaimer
Website designed by Attention Media.
|
|
